Scientists are increasingly focused on retatrutide, a innovative treatment developed by Eli Lilly, as a possible step in body loss . Unlike many existing approaches, retatrutide is a dual -action compound targeting both GLP-1 and GIP, hormones that affect appetite and glucose regulation . Early